What Does the Future Hold in the Treatment of PsA

0 out of 5 steps completed0%
0 Lessons

Course Summary

In this issue of Rheumatology Nurse Practice, we will explore the pathways that new agents under investigation for the treatment of psoriatic arthritis (PsA) are targeting. We will also examine the potential role of biosimilars for patients with PsA as they are introduced more commonly into clinical care.

Target Audience

This activity has been designed to meet the educational needs of nurses, nurse practitioners, and physician assistants. Other healthcare providers may also participate.

Learning Objectives

  • Assess the impact of commonly cited reasons that lead to underuse of biologics in patients with PsA
  • Recall key components of phase 1, 2, 3, and 4 clinical trials
  • Identify at least 3 agents under late-stage development for the treatment of PsA
  • Discuss recent data related to the real-world use of biosimilars in current clinical practice

Accreditation Statement

Rheumatology Nurses Society is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (Provider No. P0500). Rheumatology Nurses Society designates this educational activity for 3.1 total contact hours and 2.5 CNE pharmacotherapeutic contact hours.

Faculty Disclosures

According to the disclosure policy of the Rheumatology Nurses Society, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence.

Linda Grinnell-Merrick, MS, NP-BC
Speakers Bureau: AbbVie, Celgene, Janssen, Novartis
Consultant: Lilly, Sanofi

Monica Richey, MSN, ANP-CP/GNP
Nothing to disclose

Eileen Lydon, MA, RN, ANP-BC
Speakers Bureau: Novartis, AbbVie
Consultant: Horizon, Sanofi

Amanda Mixon, PA-C
Speakers Bureau: AbbVie, Lilly, Celgene, Novartis
Consultant: AbbVie, Lilly, Pfizer, Regeneron

Amy Wielgosz, RN, CCRC
Nothing to disclose

Copyright Statement

© 2019. This CNE-certified activity is held as copyrighted © by Rheumatology Nurses Society. Through this notice, the Rheumatology Nurses Society grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).